Researchers found that a newer member of the taxane family, cabazitaxel, has properties that could make it more effective for some prostate cancer patients.
Researchers also found a genomic marker that could help physicians identify which patients might benefit most from cabazitaxel.
To access this subscriber-only content please log in or subscribe.
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe